The state’s Biotechnology Task Force released a 44-page report of recommendations to the state that could help New Jersey reinvigorate its life sciences sector.
Many of the themes from the report echo comments from the Biotechnology Innovation Organization’s annual conference in Boston recently.
“Over the last two decades, the pharmaceutical footprint in New Jersey has contracted, affected by the patent cliff, the recession, mergers and acquisitions, research and manufacturing moving away from the state,” the report said. “The concentration of biopharmaceuticals has helped the state retain its position as a global hub for the medical sciences, but there is strong competition with other states and countries for startups and job creation.”
